FIG 1.

Accelerated recovery from PcP in mice treated with anti-Pneumocystis (anti-Pc) antibody, SSZ, or a combination of both. Pneumocystis-infected SCID mice were immune reconstituted with wild-type splenocytes. (A) Treatments were started at 8 days postreconstitution (arrow), when the mice displayed obvious signs of PCP (a >10% body weight loss and a >25% increase in respiratory rate). Body weight loss was used to noninvasively monitor the progression of disease following treatment. For body weight loss, values are the mean ± 1 standard error measurement (SEM). *, P < 0.05 for mice in the SSZ plus anti-Pneumocystis antibody (Ab) combination treatment group compared to the results for mice in the control treatment group at the same time; #, P < 0.05 for mice in the SSZ or anti-Pneumocystis antibody treatment group compared to the results for mice in the control treatment group at the same time. For time points up to and including day 6 posttreatment (PT), data are for ≥11 mice per group. For time points later than day 6 posttreatment, data are for ≥6 mice per group. (B and C) Pulmonary function, as assessed by dynamic lung compliance (B) and lung resistance (C), was measured at 6 and 11 days posttreatment. Values are the mean ± 1 standard error measurement. *, P < 0.05 between groups, as indicated. At the day 6 time point, data are for 4 mice per group. At the day 11 time point, data are for 5 to 7 mice per group.